LIFE, US0021202025

aTyr Pharma stock fell 5.56 percent to USD 0.17 on October 16, 2026

Published on 10/17/2026 at 20:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Market value stood at USD 17.1 million on October 16, 2026. aTyr Pharma stock closed at USD 0.17, down 5.56 percent on Nasdaq.

Nasdaq trading ended lower

Nasdaq trading finished lower on October 16, 2026.
aTyr Pharma had a market capitalization of USD 17.1 million.
aTyr Pharma stock closed at USD 0.17 at 4:00 p.m. ET on October 16, 2026, down 5.56 percent versus the Nasdaq prior close.
The trailing P/E ratio was minus 0.28 on October 16, 2026.

LIFE, US0021202025, Illustration mit AI erstellt.

aTyr Pharma stock closed at USD 0.17 on October 16, 2026 at 4:00 p.m. ET, down 5.56 percent versus the Nasdaq prior close. The move places the clinical-stage biotechnology company at a market capitalization of USD 17.1 million.

Price position and trading volume

The stock's 52-week range was USD 0.17 to USD 1.11 on October 16, 2026, leaving the closing price 84.68 percent below the 52-week high. Trading volume reached 1,801,645 shares, compared with an average volume of 3,252,112 shares.

The closing level also sits at the lower end of that annual range. The figures describe a market with a wide gap between the latest quotation and the yearly high, while the session volume remained below its average.

Valuation and company focus

aTyr Pharma's trailing P/E ratio was minus 0.28 on October 16, 2026, and its dividend yield was zero. The company describes its business as developing therapies for fibrosis and inflammation through tRNA synthetase biology, with efzofitimod as its lead therapeutic candidate, according to aTyr Pharma.

The company is investigating efzofitimod in pulmonary sarcoidosis and systemic sclerosis-related interstitial lung disease. Its investor page dated October 13, 2026 also listed a publication on the anti-fibrotic effects of ATYR0101, giving the pipeline a second clinical-development reference beyond the lead program.

Comparison with peers

aTyr Pharma: minus 5.56 percent, P/E minus 0.28, market capitalization USD 17.1 million

Moderna (Nasdaq, USD): minus 7.82 percent, P/E minus 27.32, market capitalization USD 87.0 billion

Sarepta Therapeutics (Nasdaq, USD): minus 3.88 percent, P/E minus 5.90, market capitalization USD 1.8 billion

Closing level and investor perspective

aTyr Pharma's USD 0.17 closing price on Nasdaq on October 16, 2026 came with a minus 5.56 percent daily move and a trailing P/E ratio below zero. The next market signal will come from the company's clinical and regulatory progress, rather than from dividend income.